A Giant Gastric Gastrointestinal Stromal Tumor Successfully Resected Following Neoadjuvant Treatment With Imatinib Mesylate.


Journal

Anticancer research
ISSN: 1791-7530
Titre abrégé: Anticancer Res
Pays: Greece
ID NLM: 8102988

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 09 01 2020
revised: 15 01 2020
accepted: 16 01 2020
entrez: 5 2 2020
pubmed: 6 2 2020
medline: 20 2 2020
Statut: ppublish

Résumé

Neoadjuvant treatment with imatinib mesylate (IM) has not been established for gastrointestinal stromal tumor (GIST). A case of a giant gastric GIST that was radically resected following neoadjuvant therapy with IM is reported. A 71-year-old woman with abdominal distension was referred to our hospital for treatment. Contrast-enhanced computed tomography showed a large (>30 cm), heterogeneous mass, with dilated vessels around the tumor. The diagnosis was a gastric GIST by endoscopic ultrasound-fine needle aspiration, and neoadjuvant therapy with 400 mg IM daily was started. Radical surgery was performed after 13 months. Since the tumor was not invasive, complete resection by partial gastrectomy was achieved without the need for combined resection of other organs. The patient remains alive without recurrence 12 months after surgery. A giant GIST, larger than 30 cm in size, is quite rare. Neoadjuvant IM treatment should be considered in the management of large GISTs.

Sections du résumé

BACKGROUND BACKGROUND
Neoadjuvant treatment with imatinib mesylate (IM) has not been established for gastrointestinal stromal tumor (GIST). A case of a giant gastric GIST that was radically resected following neoadjuvant therapy with IM is reported.
CASE REPORT METHODS
A 71-year-old woman with abdominal distension was referred to our hospital for treatment. Contrast-enhanced computed tomography showed a large (>30 cm), heterogeneous mass, with dilated vessels around the tumor. The diagnosis was a gastric GIST by endoscopic ultrasound-fine needle aspiration, and neoadjuvant therapy with 400 mg IM daily was started. Radical surgery was performed after 13 months. Since the tumor was not invasive, complete resection by partial gastrectomy was achieved without the need for combined resection of other organs. The patient remains alive without recurrence 12 months after surgery.
CONCLUSION CONCLUSIONS
A giant GIST, larger than 30 cm in size, is quite rare. Neoadjuvant IM treatment should be considered in the management of large GISTs.

Identifiants

pubmed: 32014967
pii: 40/2/1147
doi: 10.21873/anticanres.14056
doi:

Substances chimiques

Antineoplastic Agents 0
Protein Kinase Inhibitors 0
Imatinib Mesylate 8A1O1M485B

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1147-1152

Informations de copyright

Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Auteurs

Ryo Takahashi (R)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Takahiro Toyokawa (T)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan t-toyokawa@med.osaka-cu.ac.jp.

Mami Yoshii (M)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Tatsuro Tamura (T)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Hiroaki Tanaka (H)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Shigeru Lee (S)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Kazuya Muguruma (K)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Masakazu Yashiro (M)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Masaichi Ohira (M)

Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH